Roisin M Connolly

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment
    Roisin M Connolly
    Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA
    Clin Cancer Res 19:1651-9. 2013
  2. pmc Current approaches for neoadjuvant chemotherapy in breast cancer
    Roisin M Connolly
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 1650 Orleans Street, CRB I, Room 153, Baltimore, MD 21287 0013, United States Electronic address
    Eur J Pharmacol 717:58-66. 2013
  3. pmc Epigenetics as a therapeutic target in breast cancer
    Roisin Connolly
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21231 1000, USA
    J Mammary Gland Biol Neoplasia 17:191-204. 2012
  4. doi request reprint High-dose chemotherapy plus stem cell transplantation in advanced germ cell cancer: a review
    Roisin M Connolly
    Sidney Kimmel Comprehensive Cancer Centre, Johns Hopkins School of Medicine, 1650 Orleans Street, CRB 1, Room 186, Baltimore, MD 21231 1000, USA
    Eur Urol 56:57-64. 2009
  5. pmc Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer
    Michelle A Rudek
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB1 1M52, Baltimore, MD 21231, USA
    Breast Cancer Res Treat 139:135-43. 2013
  6. pmc Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer
    Roisin M Connolly
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1 189, Baltimore, MD 21231 1000, USA
    Breast Cancer Res Treat 127:153-62. 2011

Detail Information

Publications6

  1. pmc Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment
    Roisin M Connolly
    Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA
    Clin Cancer Res 19:1651-9. 2013
    ..Robust evaluation of RARĪ² and downstream genes may permit optimized use of retinoids in the solid tumor arena...
  2. pmc Current approaches for neoadjuvant chemotherapy in breast cancer
    Roisin M Connolly
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 1650 Orleans Street, CRB I, Room 153, Baltimore, MD 21287 0013, United States Electronic address
    Eur J Pharmacol 717:58-66. 2013
    ..We will also discuss the attractiveness of this approach to study the mechanism of action of standard and novel agents, and the role of predictive biomarkers of response to treatment and outcomes. ..
  3. pmc Epigenetics as a therapeutic target in breast cancer
    Roisin Connolly
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21231 1000, USA
    J Mammary Gland Biol Neoplasia 17:191-204. 2012
    ..We highlight initial promising results to date with use of epigenetic modifiers in patients with breast cancer and the ongoing challenges involved in the successful establishment of these agents for the treatment of breast cancer...
  4. doi request reprint High-dose chemotherapy plus stem cell transplantation in advanced germ cell cancer: a review
    Roisin M Connolly
    Sidney Kimmel Comprehensive Cancer Centre, Johns Hopkins School of Medicine, 1650 Orleans Street, CRB 1, Room 186, Baltimore, MD 21231 1000, USA
    Eur Urol 56:57-64. 2009
    ....
  5. pmc Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer
    Michelle A Rudek
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB1 1M52, Baltimore, MD 21231, USA
    Breast Cancer Res Treat 139:135-43. 2013
    ..BSA was not the main source of pharmacokinetic variability. Fixed-dose capecitabine is feasible, and simplifies dosing...
  6. pmc Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer
    Roisin M Connolly
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1 189, Baltimore, MD 21231 1000, USA
    Breast Cancer Res Treat 127:153-62. 2011
    ..However, these unexpected pharmacokinetic findings support further investigation of mechanisms underlying docetaxel elimination pathways...